Health AdultsNCT07113236
Effectiveness of Interventions for Improving HPV Vaccination Cover
A study testing Instructions, advices and No instructions in people with Health Adults and Teenager, run by Instituto Nacional de Cancerologia, Columbia at 1 site in Colombia.
Trial summary
Research Problem and Question: The development of prophylactic vaccines against the human papillomavirus (HPV) marks a major scientific and technological advance in the fight against cervical cancer. Read more about this study
- Who is it for?
- Ages 9 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Health Adults, Teenager
- What is being tested?
- Instructions, advices and No instructions
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 320 participants
- Where
- 1 siteColombia
- Study dates
- 1 Jan 2024to 31 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Public and private educational institutions recognized by the Ministry of National Education, located in municipalities with a reported HPV vaccination coverage rate of less than 25% (using the national vaccination coverage statistics for 2021 as a baseline).
- Each cluster (educational institution) will be made up of parents or guardians, educators, and children enrolled in the institution. Children must be between the ages of 9 and 17 years old and boys between 9 and 14 years old, in accordance with the guidelines of the Ministry of Health and Social Protection.
- Participants must sign informed consent, and the minor must provide informed assent if they are under 14 years old.
Who cannot join
- Children with known hypersensitivity to the active ingredients or any of the excipients of the vaccine, with acute fever, in a state of immunosuppression (e.g., HIV or prolonged use of steroids) or with a coagulation disorder will not be able to be part of the population assigned to the conglomerate.
Trial locations and contacts
1 site in 1 country.
Colombia1 site
Instituto Nacional de Cancerología
Bogotá, Cundinamarca, 111511
About this study
Official title: Effectiveness of Two Training Interventions Aimed at Increasing HPV Vaccination Coverage in Four Regions of Colombia
Research Problem and Question: The development of prophylactic vaccines against the human papillomavirus (HPV) marks a major scientific and technological advance in the fight against cervical cancer. However, translating the efficacy of these results into effectiveness in terms of reducing the disease burden in the target population requires the vaccine to be delivered within comprehensive public health programs. HPV vaccination and cervical cancer screening have not been adequately integrated. While studies have evaluated the effectiveness of different educational strategies aimed at increasing HPV vaccination acceptability and coverage, the evidence is still heterogeneous and limited. In this regard, a systematic review emphasizes that the shortcomings of the available research lie in three key aspects: a lack of coordination with the setting where the intervention is delivered, errors in selecting the most appropriate strategy, and inaccuracies in study design and conduct (risk of bias). In Colombia, there are no recent data from the same time period or by regional context that have evaluated the effectiveness of two training interventions aimed at increasing HPV vaccine coverage.
General Objective To evaluate the effectiveness of two training interventions aimed at increasing HPV vaccine coverage in four regions of Colombia.
Read more
Materials and methods Pragmatic cluster randomized controlled trial.
The study hypotheses are:
H1: The use of educational interventions does not increase HPV vaccine coverage.
H2: The use of educational interventions increases HPV vaccine coverage.
Read the detailed description
The inclusion criteria are: public and private educational institutions recognized by the Ministry of National Education, located in municipalities with a reported HPV vaccination coverage rate of less than 25% (using the national 2021 vaccination coverage statistics as a baseline). Parents or guardians, the educational community, and children attending the selected institution will participate. Children must be between the ages of 9 and 17 years old and boys between 9 and 14 years old, in accordance with the guidelines of the Ministry of Health and Social Protection. To estimate the sample size, the method suggested by Campbell and van Brukelen was implemented, which requires the participation of 12 groups of 100 participants (n=1,200). For each municipality, schools will be selected using the official list of educational institutions provided by the Ministry of Education as a sampling framework. Simple random sampling will be used. The randomization and analysis units will be educational institutions randomly assigned in a 1:1:1 ratio to the control or intervention group. All study arms will receive psychosocial training with training from health professionals and teachers from the selected municipalities, defined within the community setting. Within the school-based intervention, the behavioral component will use two strategies implemented with an approach to biopsychosocial models: the health belief model, the theory of planned behavior, social cognitive theory, or the theory of reasoned action. The outcomes to be measured will be: the proportion of participants (boys and girls aged 9-17 years and boys aged 9-14 years, in accordance with the guidelines of the Ministry of Health and Social Protection) exposed to the intervention who receive a dose of vaccine during the first 30 days after the intervention, the degree of acceptability of vaccination, and the effectiveness of the training strategies in increasing HPV vaccination coverage. Statistical analysis will be performed following the "Intent-to-Treat (ITT)" principle. The primary outcome will be assessed between the intervention and control groups using a two-dimensional multilevel model, with participants nested within each educational institution. The model will be adjusted for covariates at the individual level (Level 1: student sex and age) and the educational setting (Level 2: nature of the educational institution, religious education, and geographic area). Data will be analyzed using R software version 4.4.1 (RStudio 2021.09.0).
Expected Impact The development of this project will allow for the design and implementation of a program to improve vaccination coverage with the quadrivalent human papillomavirus (HPV) vaccine in Colombia.
Analysis plan: the primary outcome will be assessed during the first 30 days after administering the intervention, and statistical analysis will be performed following the "Intent-to-Treat (ITT)" principle. The intention-to-treat population is defined as all participants registered for the training intervention, regardless of their compliance. The primary outcome will be measured during the first 30 days after the intervention, emphasizing that receiving at least one dose of HPV vaccination will be considered the outcome of interest. The population exposed to the intervention who has not received the vaccine at the end of the observation period will be followed up by a member of the research group, who will determine, through home visits, whether the non-vaccination was due to lack of consent or assent, or because they were deemed no longer needed (e.g., initiation of sexual activity, teenage pregnancy). If home contact is not feasible, telephone and written (email) communication will be established to determine whether the non-vaccination was a consequence of migration or displacement from the territory. If contact is not feasible, loss to follow-up will be considered. Sensitivity analyses will be performed to assess the robustness of the conclusions based on the percentage of losses to follow-up.
The primary outcome will be assessed in each intervention group and then compared to the control group using a two-dimensional multilevel model, with participants nested within each cluster (educational institution). The model will be adjusted for covariates at the individual level (level 1: student sex and age) and the educational setting (level 2: nature of the educational institution, religious education, and geographic area). Data will be analyzed using R software version 4.4.1 (RStudio 2021.09.0). Descriptive statistics will be applied to the sociodemographic variables. Measures of central tendency and dispersion will be estimated for continuous data, and absolute and relative frequencies will be used for qualitative data. Frequency and distribution will be examined for categorical variables, and normal distribution and homogeneity of variance will be analyzed for continuous variables. For categorical variables, the differences between each intervention group and the control group will be analyzed using Fisher's exact test or Pearson's chi-square test. Continuous variables will be compared between each intervention group and the control group using the Mann-Whitney test or Student's t test, depending on the presence or absence of normal distribution of the data. Multivariate logistic regression will be implemented to adjust the association of interest for the presence of the previously mentioned level one and two covariates.
A Bonferroni correction will be performed for the level of significance. Confidence intervals will be estimated, and the adjusted and unadjusted odds ratios (OR and OR) will be implemented as measures of association. The study protocol must be previously approved by the Ethics Committee of the National Cancer Institute as the executing entity.
- Conditions
- Health Adults, Teenager
- Being tested
- Instructions, advices, No instructions
- Keywords
- Human papillomavirus, vaccination, Uterine Cervical Neoplasms, communitarian intervention, Psychosocial Intervention
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Instructions, advicesBehavioural
A first moment: informed conversation and exploration of myths and realities with the aim of exploring the perceptions and attitudes of participating children and adolescents towards the vaccine against HPV-associated cancers through an open and reflective dialogue; a second moment with the presentation of a testimonial video and reflection with the aim of learning from the experiences of others, finding inspiration and motivation in their stories, and feeling connected with other people; and a third moment of 360° feedback with the aim of receiving final information about HPV, HPV-associated cancers, and the importance of vaccination.
No instructionsOther
No instructions for vaccination
| Study group | Role | What they receive |
|---|---|---|
| Instructions by Health professional | Experimental | Instructions by health professional Receives: Behavioral: Instructions, advices |
| Control | Active comparator | no instructions Receives: Other: No instructions |
| Instructions by teachers | Experimental | Instructions by teachers for vaccination Receives: Behavioral: Instructions, advices |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of vaccination
Proportion of participants who would accept vaccination after the training intervention with a score equal to or greater than 4 on a 1 to 5 Likert scale that qualitatively expresses the degree of agreement with HPV vaccination).
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2025
- Study start1 Jan 2024
- Primary completion30 Apr 2025
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Health AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Advisor and counselor for vaccination
- Masking
- None (open label)
- Enrolment
- 320 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Nacional de Cancerologia, Columbia
- Sponsor type
- Other government
- Collaborators
- Universidad de Cartagena
- Responsible party
- Sponsor
- Investigators
- Alba Cómbita, Phd, Study chair, Instituto Nacional de Cancerologia, ColumbiaJuliana Rodriguez, Ginecologisth oncologist, Study chair, Instituto Nacional de Cancerologia, ColumbiaCarolina Wiesner, Director, Study director, Instituto Nacional de Cancerologia, Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07113236
- Sponsor's protocol ID
- C19010300-582
- Status last verified
- Aug 2025
- First submitted
- 27 Jun 2025
- Last updated
- 21 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Two Training Interventions Aimed at Increasing HPV Vaccination Coverage in Four Regions of Colombia
- ClinicalTrials.gov ID
- NCT07113236
- Acronym / sponsor ID
- C19010300-582
- Conditions
- Health Adults, Teenager
- Keywords
- Human papillomavirus, vaccination, Uterine Cervical Neoplasms, communitarian intervention, Psychosocial Intervention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 320 participants (actual)
- Lead sponsor
- Instituto Nacional de Cancerologia, ColumbiaOther government
- Collaborators
- Universidad de Cartagena
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 8 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research Problem and Question: The development of prophylactic vaccines against the human papillomavirus (HPV) marks a major scientific and technological advance in the fight against cervical cancer. However, translating the efficacy of these results into effectiveness in terms of reducing the disease burden in the target population requires the vaccine to be delivered within comprehensive public health programs. HPV vaccination and cervical cancer screening have not been adequately integrated. While studies have evaluated the effectiveness of different educational strategies aimed at increasing HPV vaccination acceptability and coverage, the evidence is still heterogeneous and limited. In this regard, a systematic review emphasizes that the shortcomings of the available research lie in three key aspects: a lack of coordination with the setting where the intervention is delivered, errors in selecting the most appropriate strategy, and inaccuracies in study design and conduct (risk of bias). In Colombia, there are no recent data from the same time period or by regional context that have evaluated the effectiveness of two training interventions aimed at increasing HPV vaccine coverage.
General Objective To evaluate the effectiveness of two training interventions aimed at increasing HPV vaccine coverage in four regions of Colombia.
Materials and methods Pragmatic cluster randomized controlled trial.
The study hypotheses are:
H1: The use of educational interventions does not increase HPV vaccine coverage.
H2: The use of educational interventions increases HPV vaccine coverage.
Detailed description
The inclusion criteria are: public and private educational institutions recognized by the Ministry of National Education, located in municipalities with a reported HPV vaccination coverage rate of less than 25% (using the national 2021 vaccination coverage statistics as a baseline). Parents or guardians, the educational community, and children attending the selected institution will participate. Children must be between the ages of 9 and 17 years old and boys between 9 and 14 years old, in accordance with the guidelines of the Ministry of Health and Social Protection. To estimate the sample size, the method suggested by Campbell and van Brukelen was implemented, which requires the participation of 12 groups of 100 participants (n=1,200). For each municipality, schools will be selected using the official list of educational institutions provided by the Ministry of Education as a sampling framework. Simple random sampling will be used. The randomization and analysis units will be educational institutions randomly assigned in a 1:1:1 ratio to the control or intervention group. All study arms will receive psychosocial training with training from health professionals and teachers from the selected municipalities, defined within the community setting. Within the school-based intervention, the behavioral component will use two strategies implemented with an approach to biopsychosocial models: the health belief model, the theory of planned behavior, social cognitive theory, or the theory of reasoned action. The outcomes to be measured will be: the proportion of participants (boys and girls aged 9-17 years and boys aged 9-14 years, in accordance with the guidelines of the Ministry of Health and Social Protection) exposed to the intervention who receive a dose of vaccine during the first 30 days after the intervention, the degree of acceptability of vaccination, and the effectiveness of the training strategies in increasing HPV vaccination coverage. Statistical analysis will be performed following the "Intent-to-Treat (ITT)" principle. The primary outcome will be assessed between the intervention and control groups using a two-dimensional multilevel model, with participants nested within each educational institution. The model will be adjusted for covariates at the individual level (Level 1: student sex and age) and the educational setting (Level 2: nature of the educational institution, religious education, and geographic area). Data will be analyzed using R software version 4.4.1 (RStudio 2021.09.0).
Expected Impact The development of this project will allow for the design and implementation of a program to improve vaccination coverage with the quadrivalent human papillomavirus (HPV) vaccine in Colombia.
Analysis plan: the primary outcome will be assessed during the first 30 days after administering the intervention, and statistical analysis will be performed following the "Intent-to-Treat (ITT)" principle. The intention-to-treat population is defined as all participants registered for the training intervention, regardless of their compliance. The primary outcome will be measured during the first 30 days after the intervention, emphasizing that receiving at least one dose of HPV vaccination will be considered the outcome of interest. The population exposed to the intervention who has not received the vaccine at the end of the observation period will be followed up by a member of the research group, who will determine, through home visits, whether the non-vaccination was due to lack of consent or assent, or because they were deemed no longer needed (e.g., initiation of sexual activity, teenage pregnancy). If home contact is not feasible, telephone and written (email) communication will be established to determine whether the non-vaccination was a consequence of migration or displacement from the territory. If contact is not feasible, loss to follow-up will be considered. Sensitivity analyses will be performed to assess the robustness of the conclusions based on the percentage of losses to follow-up.
The primary outcome will be assessed in each intervention group and then compared to the control group using a two-dimensional multilevel model, with participants nested within each cluster (educational institution). The model will be adjusted for covariates at the individual level (level 1: student sex and age) and the educational setting (level 2: nature of the educational institution, religious education, and geographic area). Data will be analyzed using R software version 4.4.1 (RStudio 2021.09.0). Descriptive statistics will be applied to the sociodemographic variables. Measures of central tendency and dispersion will be estimated for continuous data, and absolute and relative frequencies will be used for qualitative data. Frequency and distribution will be examined for categorical variables, and normal distribution and homogeneity of variance will be analyzed for continuous variables. For categorical variables, the differences between each intervention group and the control group will be analyzed using Fisher's exact test or Pearson's chi-square test. Continuous variables will be compared between each intervention group and the control group using the Mann-Whitney test or Student's t test, depending on the presence or absence of normal distribution of the data. Multivariate logistic regression will be implemented to adjust the association of interest for the presence of the previously mentioned level one and two covariates.
A Bonferroni correction will be performed for the level of significance. Confidence intervals will be estimated, and the adjusted and unadjusted odds ratios (OR and OR) will be implemented as measures of association. The study protocol must be previously approved by the Ethics Committee of the National Cancer Institute as the executing entity.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Advisor and counselor for vaccination
| Arm | Type | Receives |
|---|---|---|
| Instructions by Health professional | Experimental | Behavioral: Instructions, advicesInstructions by health professional |
| Control | Active comparator | Other: No instructionsno instructions |
| Instructions by teachers | Experimental | Behavioral: Instructions, advicesInstructions by teachers for vaccination |
Who may qualify
- Ages
- 9 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Public and private educational institutions recognized by the Ministry of National Education, located in municipalities with a reported HPV vaccination coverage rate of less than 25% (using the national vaccination coverage statistics for 2021 as a baseline).
- Each cluster (educational institution) will be made up of parents or guardians, educators, and children enrolled in the institution. Children must be between the ages of 9 and 17 years old and boys between 9 and 14 years old, in accordance with the guidelines of the Ministry of Health and Social Protection.
- Participants must sign informed consent, and the minor must provide informed assent if they are under 14 years old.
Key exclusion criteria (1 listed)
- Children with known hypersensitivity to the active ingredients or any of the excipients of the vaccine, with acute fever, in a state of immunosuppression (e.g., HIV or prolonged use of steroids) or with a coagulation disorder will not be able to be part of the population assigned to the conglomerate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Instructions, advicesA first moment: informed conversation and exploration of myths and realities with the aim of exploring the perceptions and attitudes of participating children and adolescents towards the vaccine against HPV-associated cancers through an open and reflective dialogue; a second moment with the presentation of a testimonial video and reflection with the aim of learning from the experiences of others, finding inspiration and motivation in their stories, and feeling connected with other people; and a third moment of 360° feedback with the aim of receiving final information about HPV, HPV-associated cancers, and the importance of vaccination. | Behavioural | Instructions by Health professional, Instructions by teachers |
| No instructionsNo instructions for vaccination | Other | Control |
Primary outcome
Acceptability of vaccination
Time frame: 12 months
Proportion of participants who would accept vaccination after the training intervention with a score equal to or greater than 4 on a 1 to 5 Likert scale that qualitatively expresses the degree of agreement with HPV vaccination).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Health Adults
RecruitingPhase 1/2
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Enrolling by invitationObservational study
Sustaining Health After an Intensive Weight-loss Pro-gramme
Obesity & Overweight, Weight Loss
Not yet recruitingPhase 1
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Health Adults, Asthma
Recruiting
The Young Adults' Experiences With Virtual Reality (YAES VR) Study
Population Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alba Cómbita, Phd study chair
Instituto Nacional de Cancerologia, Columbia
Juliana Rodriguez, Ginecologisth oncologist study chair
Instituto Nacional de Cancerologia, Columbia
Carolina Wiesner, Director study director
Instituto Nacional de Cancerologia, Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Instructions, advices and No instructions in people with Health Adults and Teenager, run by Instituto Nacional de Cancerologia, Columbia at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability of vaccination (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2025.